FibroGen Inc (FGEN)

1.14 +0.01 (+0.88%) USD  |  NASDAQ  |  May 03, 16:00
1.125 -0.02 (-1.32%) Pre-Market: 20:00
More

FibroGen Research and Development Expense (Quarterly): 51.70M for Dec. 31, 2023

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2013. Upgrade now.
Date Value
December 31, 2023 51.70M
September 30, 2023 61.19M
June 30, 2023 95.48M
March 31, 2023 74.49M
December 31, 2022 61.63M
September 30, 2022 75.18M
June 30, 2022 70.96M
March 31, 2022 89.02M
December 31, 2021 113.92M
September 30, 2021 75.88M
June 30, 2021 122.57M
March 31, 2021 74.68M
December 31, 2020 78.13M
September 30, 2020 58.48M
June 30, 2020 61.41M
March 31, 2020 54.90M
December 31, 2019 56.80M
September 30, 2019 49.96M
June 30, 2019 52.01M
March 31, 2019 50.50M
December 31, 2018 70.28M
Date Value
September 30, 2018 56.44M
June 30, 2018 52.14M
March 31, 2018 56.97M
December 31, 2017 52.47M
September 30, 2017 50.34M
June 30, 2017 46.98M
March 31, 2017 46.73M
December 31, 2016 50.61M
September 30, 2016 40.56M
June 30, 2016 52.39M
March 31, 2016 43.65M
December 31, 2015 59.92M
September 30, 2015 52.07M
June 30, 2015 51.56M
March 31, 2015 50.54M
December 31, 2014 51.26M
September 30, 2014 40.62M
June 30, 2014 33.27M
March 31, 2014 25.65M
December 31, 2013 29.43M
September 30, 2013 23.18M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

49.96M
Minimum
Sep 2019
122.57M
Maximum
Jun 2021
72.55M
Average
70.96M
Median
Jun 2022

Research and Development Expense (Quarterly) Benchmarks

Annovis Bio Inc 8.905M
Emergent BioSolutions Inc 29.40M
Vertex Pharmaceuticals Inc 824.60M
Geron Corp 29.37M
Regeneron Pharmaceuticals Inc 1.248B